Bruno G, Merletti F, Biggeri A, Bargero G, Prina-Cerai S, Pagano G, Cavallo-Perin P
Department of Internal Medicine, University of Turin, I-10126 Turin, Italy.
Diabetologia. 2006 May;49(5):937-44. doi: 10.1007/s00125-006-0195-6. Epub 2006 Mar 9.
AIMS/HYPOTHESIS: Measurement of plasma apolipoprotein (Apo) B may improve prediction of cardiovascular risk, as it provides a measure of the total number of atherogenic particles. The aim of this population-based study was to compare the association of non-HDL-cholesterol, ApoB and the ApoB:ApoA-I ratio with cardiovascular mortality in people with type 2 diabetes.
We assessed the association of lipids, lipoprotein lipids and apolipoproteins with 11-year mortality from cardiovascular disease in the population-based cohort of the Casale Monferrato Study (1,565 people with diabetes; median age 68.9 years), and determined the effect of age (< or =70 and >70 years) on these relationships.
On the basis of 341 deaths from cardiovascular disease in 10,809 person-years of observation, there was a decreasing trend in risk adjusted for multiple factors across quartiles of total cholesterol, and LDL- and non-HDL-cholesterol in people aged >70 years, but no trend in those aged < or =70 years. Age did not affect the protective effect of HDL-cholesterol. ApoB and ApoB:ApoA-I were associated with outcome in people in both age groups independently of non-HDL-cholesterol. After adjustment for multiple factors, including non-HDL-cholesterol, the hazard ratios for ApoB:ApoA-I in the upper vs lower quartile were 2.98 (95% CI 1.15-7.75; p for trend=0.009) for people aged < or =70 years and 1.94 (95% CI 1.20-3.13; p for trend=0.003) for those aged >70 years.
CONCLUSIONS/INTERPRETATION: In this cohort of Mediterranean subjects with diabetes, ApoB and the ApoB:ApoA-I ratio were associated with cardiovascular disease mortality independently of non-HDL-cholesterol. Our findings support the recommendation that ApoB and ApoA-I should be measured routinely in all people with diabetes, particularly in the elderly.
目的/假设:血浆载脂蛋白(Apo)B的测量可能会改善心血管疾病风险的预测,因为它提供了致动脉粥样硬化颗粒总数的一种度量。这项基于人群的研究旨在比较2型糖尿病患者中非高密度脂蛋白胆固醇、ApoB以及ApoB与ApoA-I比值和心血管疾病死亡率之间的关联。
我们在卡萨莱蒙费拉托研究的基于人群的队列中(1565例糖尿病患者;中位年龄68.9岁)评估了脂质、脂蛋白脂质和载脂蛋白与心血管疾病11年死亡率之间的关联,并确定了年龄(≤70岁和>70岁)对这些关系的影响。
在10809人年的观察期内,共有341例心血管疾病死亡病例。在年龄>70岁的人群中,经多因素调整后的风险在总胆固醇、低密度脂蛋白胆固醇和非高密度脂蛋白胆固醇的四分位数之间呈下降趋势,但在年龄≤70岁的人群中无此趋势。年龄并不影响高密度脂蛋白胆固醇的保护作用。ApoB和ApoB与ApoA-I比值在两个年龄组中均与结局相关,且独立于非高密度脂蛋白胆固醇。在对包括非高密度脂蛋白胆固醇在内的多因素进行调整后,年龄≤70岁人群中,ApoB与ApoA-I比值处于上四分位数与下四分位数相比的风险比为2.98(95%可信区间1.15-7.75;趋势p值=0.009),年龄>70岁人群中为1.94(95%可信区间1.20-3.13;趋势p值=0.003)。
结论/解读:在这个地中海地区糖尿病患者队列中,ApoB和ApoB与ApoA-I比值独立于非高密度脂蛋白胆固醇与心血管疾病死亡率相关。我们的研究结果支持在所有糖尿病患者中,尤其是老年人中常规测量ApoB和ApoA-I的建议。